Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: Correlation to rejection and posttransplantation coronary artery disease

R. H. Kerman, B. Susskind, David H Kerman, M. Lam, K. Gerolami, J. Williams, R. Kalish, M. Campbell, S. Katz, C. T. Van Buren, H. Frazier, B. Radovancevic, S. Fife, B. Kahan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Screening pretransplantation recipient sera for percent panel reactive antibodies (%PRA) by an anti-human globulin (AHG) assay may identify recipients who are at risk for graft rejection or development of posttransplantation coronary artery disease. However, the pretransplantation AHG-%PRA does not always correlate with the occurrence of graft rejection or coronary artery disease. Methods: We compared the predictive capacity of the AHG-%PRA with that of an enzyme-linked immunoassay (EIA)-based PRA assay that identifies immunoglobulin G bound to soluble human leukocyte antigen (sHLA) class I molecules from pooled platelets of 240 random donors (sHLA-EIA), and that of an EIA-based assay that detects immunoglobulin G anti-HLA class I antibodies bound to sHLA derived from individual HLA-typed cell cultures (PRA-STAT). The pretransplantation sera from 130 cardiac allograft recipients were comparatively tested and results evaluated. Results: Although AHG-%PRA- and sHLA-EIA-determined PRA results were comparable, neither assay discriminated potential recipients at risk for rejection or coronary artery disease. However, cardiac allograft recipients with pretransplantation PRA- STAT sera > 10% were at risk for (1) graft rejection (77% vs 56%, p < .05); (2) more rejections/recipient (1.9 vs 1.0, p < .02); (3) graft rejection within 30 days (92% vs 38%, p < .001); or (4) development of coronary artery disease (48% vs 23%, p < .05) than recipients with pretransplantation PRA- STAT sera < 10%. Conclusions: PRA-STAT analysis of pretransplantation sera from potential cardiac allograft recipients may be more clinically informative about HLA alloimmunity and a better predictor of adverse clinical events than either AHG-%PRA- or sHLA-EIA-determined PRA.

Original languageEnglish
Pages (from-to)789-794
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume17
Issue number8
StatePublished - Sep 7 1998
Externally publishedYes

Fingerprint

Globulins
HLA Antigens
Immunoenzyme Techniques
Graft Rejection
Coronary Artery Disease
Antibodies
Allografts
Serum
Immunoglobulin G
Immunoglobulin Isotypes
Anti-Idiotypic Antibodies
Blood Platelets
Cell Culture Techniques
Transplant Recipients
Tissue Donors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients : Correlation to rejection and posttransplantation coronary artery disease. / Kerman, R. H.; Susskind, B.; Kerman, David H; Lam, M.; Gerolami, K.; Williams, J.; Kalish, R.; Campbell, M.; Katz, S.; Van Buren, C. T.; Frazier, H.; Radovancevic, B.; Fife, S.; Kahan, B.

In: Journal of Heart and Lung Transplantation, Vol. 17, No. 8, 07.09.1998, p. 789-794.

Research output: Contribution to journalArticle

Kerman, R. H. ; Susskind, B. ; Kerman, David H ; Lam, M. ; Gerolami, K. ; Williams, J. ; Kalish, R. ; Campbell, M. ; Katz, S. ; Van Buren, C. T. ; Frazier, H. ; Radovancevic, B. ; Fife, S. ; Kahan, B. / Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients : Correlation to rejection and posttransplantation coronary artery disease. In: Journal of Heart and Lung Transplantation. 1998 ; Vol. 17, No. 8. pp. 789-794.
@article{3b241e36c9ab48f2a89610aa34de002d,
title = "Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: Correlation to rejection and posttransplantation coronary artery disease",
abstract = "Background: Screening pretransplantation recipient sera for percent panel reactive antibodies ({\%}PRA) by an anti-human globulin (AHG) assay may identify recipients who are at risk for graft rejection or development of posttransplantation coronary artery disease. However, the pretransplantation AHG-{\%}PRA does not always correlate with the occurrence of graft rejection or coronary artery disease. Methods: We compared the predictive capacity of the AHG-{\%}PRA with that of an enzyme-linked immunoassay (EIA)-based PRA assay that identifies immunoglobulin G bound to soluble human leukocyte antigen (sHLA) class I molecules from pooled platelets of 240 random donors (sHLA-EIA), and that of an EIA-based assay that detects immunoglobulin G anti-HLA class I antibodies bound to sHLA derived from individual HLA-typed cell cultures (PRA-STAT). The pretransplantation sera from 130 cardiac allograft recipients were comparatively tested and results evaluated. Results: Although AHG-{\%}PRA- and sHLA-EIA-determined PRA results were comparable, neither assay discriminated potential recipients at risk for rejection or coronary artery disease. However, cardiac allograft recipients with pretransplantation PRA- STAT sera > 10{\%} were at risk for (1) graft rejection (77{\%} vs 56{\%}, p < .05); (2) more rejections/recipient (1.9 vs 1.0, p < .02); (3) graft rejection within 30 days (92{\%} vs 38{\%}, p < .001); or (4) development of coronary artery disease (48{\%} vs 23{\%}, p < .05) than recipients with pretransplantation PRA- STAT sera < 10{\%}. Conclusions: PRA-STAT analysis of pretransplantation sera from potential cardiac allograft recipients may be more clinically informative about HLA alloimmunity and a better predictor of adverse clinical events than either AHG-{\%}PRA- or sHLA-EIA-determined PRA.",
author = "Kerman, {R. H.} and B. Susskind and Kerman, {David H} and M. Lam and K. Gerolami and J. Williams and R. Kalish and M. Campbell and S. Katz and {Van Buren}, {C. T.} and H. Frazier and B. Radovancevic and S. Fife and B. Kahan",
year = "1998",
month = "9",
day = "7",
language = "English",
volume = "17",
pages = "789--794",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients

T2 - Correlation to rejection and posttransplantation coronary artery disease

AU - Kerman, R. H.

AU - Susskind, B.

AU - Kerman, David H

AU - Lam, M.

AU - Gerolami, K.

AU - Williams, J.

AU - Kalish, R.

AU - Campbell, M.

AU - Katz, S.

AU - Van Buren, C. T.

AU - Frazier, H.

AU - Radovancevic, B.

AU - Fife, S.

AU - Kahan, B.

PY - 1998/9/7

Y1 - 1998/9/7

N2 - Background: Screening pretransplantation recipient sera for percent panel reactive antibodies (%PRA) by an anti-human globulin (AHG) assay may identify recipients who are at risk for graft rejection or development of posttransplantation coronary artery disease. However, the pretransplantation AHG-%PRA does not always correlate with the occurrence of graft rejection or coronary artery disease. Methods: We compared the predictive capacity of the AHG-%PRA with that of an enzyme-linked immunoassay (EIA)-based PRA assay that identifies immunoglobulin G bound to soluble human leukocyte antigen (sHLA) class I molecules from pooled platelets of 240 random donors (sHLA-EIA), and that of an EIA-based assay that detects immunoglobulin G anti-HLA class I antibodies bound to sHLA derived from individual HLA-typed cell cultures (PRA-STAT). The pretransplantation sera from 130 cardiac allograft recipients were comparatively tested and results evaluated. Results: Although AHG-%PRA- and sHLA-EIA-determined PRA results were comparable, neither assay discriminated potential recipients at risk for rejection or coronary artery disease. However, cardiac allograft recipients with pretransplantation PRA- STAT sera > 10% were at risk for (1) graft rejection (77% vs 56%, p < .05); (2) more rejections/recipient (1.9 vs 1.0, p < .02); (3) graft rejection within 30 days (92% vs 38%, p < .001); or (4) development of coronary artery disease (48% vs 23%, p < .05) than recipients with pretransplantation PRA- STAT sera < 10%. Conclusions: PRA-STAT analysis of pretransplantation sera from potential cardiac allograft recipients may be more clinically informative about HLA alloimmunity and a better predictor of adverse clinical events than either AHG-%PRA- or sHLA-EIA-determined PRA.

AB - Background: Screening pretransplantation recipient sera for percent panel reactive antibodies (%PRA) by an anti-human globulin (AHG) assay may identify recipients who are at risk for graft rejection or development of posttransplantation coronary artery disease. However, the pretransplantation AHG-%PRA does not always correlate with the occurrence of graft rejection or coronary artery disease. Methods: We compared the predictive capacity of the AHG-%PRA with that of an enzyme-linked immunoassay (EIA)-based PRA assay that identifies immunoglobulin G bound to soluble human leukocyte antigen (sHLA) class I molecules from pooled platelets of 240 random donors (sHLA-EIA), and that of an EIA-based assay that detects immunoglobulin G anti-HLA class I antibodies bound to sHLA derived from individual HLA-typed cell cultures (PRA-STAT). The pretransplantation sera from 130 cardiac allograft recipients were comparatively tested and results evaluated. Results: Although AHG-%PRA- and sHLA-EIA-determined PRA results were comparable, neither assay discriminated potential recipients at risk for rejection or coronary artery disease. However, cardiac allograft recipients with pretransplantation PRA- STAT sera > 10% were at risk for (1) graft rejection (77% vs 56%, p < .05); (2) more rejections/recipient (1.9 vs 1.0, p < .02); (3) graft rejection within 30 days (92% vs 38%, p < .001); or (4) development of coronary artery disease (48% vs 23%, p < .05) than recipients with pretransplantation PRA- STAT sera < 10%. Conclusions: PRA-STAT analysis of pretransplantation sera from potential cardiac allograft recipients may be more clinically informative about HLA alloimmunity and a better predictor of adverse clinical events than either AHG-%PRA- or sHLA-EIA-determined PRA.

UR - http://www.scopus.com/inward/record.url?scp=0031708127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031708127&partnerID=8YFLogxK

M3 - Article

C2 - 9730428

AN - SCOPUS:0031708127

VL - 17

SP - 789

EP - 794

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 8

ER -